

Electronic Data Capture

EHDN Biomarkers Meeting

London, 15 Jan 2016








Overview

 HDClarity participants are selected from Enroll-HD and the Enroll-HD electronic data capture system (EDC) is used







Overview

- The HDClarity Screening Visit occurs 0-60 days after the Enroll-HD visit
- The HDClarity **Sampling Visit** occurs 1-30 days after screening, i.e. participants complete Enroll-HD core assessments within 3 months:
 - Height and weight
 - UHDRS (motor, functional assessment scale, independence score and TFC)
 - Problem Behaviour Assessment (short form)
 - Cognitive (catergorical verbal fluency, Stroop word and colour, and SDMT)
- Waivers may be granted at the discretion of the CI and the Enroll-HD core assessments may be performed at the Screening Visit if necessary





Overview

HDClarity Day >-90	HDClarity Day – 90	HDClarity Day -30	HDClarity Day -1	HDClarity Day 0	HDClarity Day 3	HDClarity Day 56	HDClarity Day 59	Waiver required
			Enroll-HD & HDClarity Screening	HDClarity Sampling	HDClarity Phone Visit			I I No I
	I I I I I I I I I I I I I I I I I I I	HDClarity Screening		HDClarity Sampling	HDClarity Phone Visit	Optional Repeat Sampling	I HDClarity Phone Visit	
Enroll-HD		HDClarity Screening		HDClarity Sampling	HDClarity Phone Visit	Optional Repeat Sampling	HDClarity Phone Visit	Core assessments out of window
	Enroll-HD & HDClarity Screening			HDClarity Sampling	HDClarity Phone Visit	Optional Repeat Sampling	HDClarity Phone Visit	Sampling visit out of window





Enroll-HD General Forms

In addition to the Enroll-HD core assessments, the following general CRFs must be checked and updated during HDClarity visits

- Demographics
- Variable
- Comorbidities
- Medications
- Clinical Trials





HDClarity Screening Visit

- There are 3 HDClarity-specific forms at the Screening Visit:
 - Enrollment CLR
 - Safety Lab Exam
 - Checklist



Enrollment CLR

• Warnings are automatically generated if inclusion/exclusion criteria aren't met

If participants do not fulfil all criteria they may be rescreened with prior

approval of the CI


- If eligibility is set to 'no' then a waiver option appears
- Local Participant Classification and burden of pathology are calculated for the date of the HDClarity Screening Visit using most recent values for DOB, CAG and UHDRS

Eligibility		
Did the participant pass the yes eligibility criteria?		t
Local Participant Classification		
Related Items:		
Enroll-HD Participant Category	manifest/motor-manifest HD	
Date of Birth	01/01/1965	
Local CAG	40	
Enroll-HD UHDRS Diagnostic Confidence Level	4	
Enroll-HD UHDRS Total Functional Capacity Score	11	
Disease burden score at time of 230 screening visit:		t
ocal participant classification at learly HD ime of screening visit:		ſ



Safety Lab Exam

- Up to 15ml venous blood:
 - Full blood count including platelet number
 - Clotting profile
 - C-reactive protein
- Upper and lower limits based on local clinical standards (≤ x2 upper limit permitted for CRP)
- If results fall out of range then re-screening may be allowed with prior approval of CI





Checklist

- If Enroll-HD core assessments are completed within the 60 day window before the Screening Visit the table will appear pre-populated
- If the visit is out of window, user must confirm a CI waiver granted has been given to complete the assessments on the same day


Have the following forms been co	mpleted for this visit?
General Variable:	yes O no
Comorbid:	yes O no
Pharmacotherapy:	yes O no
Nutritional Supplements:	yes O no
Non-Pharmacotherapy:	yes O no
Enroll-HD Core Assessments available	yes
within 60 days from screening	,
Source Visit of Core Assessments	Enroll-HD Baseline Visit (01/08/2016)
- Enroll-HD UHDRS Motor	signed
- Enroll-HD UHDRS TFC	signed
- Enroll-HD UHDRS Function	signed
- Enroll-HD Cognitive	signed
- Enroll-HD PBA-s	signed
Enroll-HD core assessment completed within 60 days from screening:	yes O no
Was this participant recruited into Enroll-HD because of participation in HD Clarity:	yes O no



HDClarity Sampling Visit

To be completed within 30 days of screening

- There are 5 HDClarity-specific forms at the Sampling Visit:
 - Eligibility Check
 - Checklist
 - CSF
 - CSF Quality
 - Blood Processing



- Eligibility and Checklist are used to confirm consent, compliance and safety before sampling
- The Enroll-HD Variable and Motor CRFs must also be completed at the Sampling Visit

CSF

- LP should be performed between 08:00 and 10:30
- If CSF cannot be obtained, up to three needles or adjacent space may be used (max 5 attempts)
- If 1ml CSF is macroscopically bloody, tube is discarded and CSF continued with new tube.
- Kit ID and all tube IDs are entered in CRF

CSF Collection			
LAB-ID:	L188998770		T P
Date and time CSF collection procedure is started:		GMT mm/dd/yyyy hh:mm	Ø.P
Total volume of CSF obtained:	ml		4
Total volume of usable CSF obtained:	ml		ØP
Kit ID:			4
Time CSF collection procedure is completed:	: hh:mm		Ø.
Number of LP attempts:	O1 O2 O3		T P
CSF Processing			
Time CSF processing is started:	: hh:mm		ØQ
Time CSF processing is completed:	: hh:mm		T P
CSF Tube Rack ID:			4
CSF aliquot:	Tube ID:		ØQ
	Quantity:		4 0
Cells from CSF:	Tube ID:		ØQ
	Quantity:		ØQ



CSF Quality

- 200 μl CSF used to determine white blood cell count and erythrocyte count per μl according to local GLPapproved laboratory practice.
- This should be done in triplicate within 60 minutes of collection and all values recorded in the CRF.

Onsite CSF Sample Quality co	ntrol		
Microscopic erythrocyte count in CSF in triplicate:	1. Count:	erys/µl	Ø P
cor in diplicater	2. Count:	erys/µl	Ø P
	3. Count:	erys/µl	Ø (
	Flag:		Ø ()
Microscopic leukocyte count in CSF in triplicate:	1. Count:	cells/µl	ØP
	2. Count:	cells/µl	Ø P
	3. Count:	cells/µl	7
	Flag:		ØP



Blood Processing

- Venous blood is drawn immediately after CSF collection is complete
 - -1 x 8.5 ml serum tube
 - 4 x 10 ml blood in lithium heparin tubes
- Tube IDs are entered in the CRF

Blood Processing			
LAB-ID:	L188998770		2 P
Date and time of blood draw:		GMT mm/dd/yyyy hh:mm	20
Lithium heparin:	Tube ID:		40
	Quantity:		2 0
Serum:	Tubes ID:		20
	Quantity:		40
	Time serum processing is started:	hh:mm	4
	Time serum processing is completed:	: hh:mm	40
Plasma:	Tubes ID:		4 0
	Quantity:		2 0
	Tube rack ID:		ØP
	Time plasma processing is started:	: hh:mm	20
	Time plasma processing is completed:	: hh:mm	40
On site Sample Storage			
Date and time samples are stored on site:	7 :	GMT mm/dd/yyyy hh:mm	Ø P



Phone Contact Occurs 24-72 hours post LP


 The participant is contacted 24 to 72 hours following optional Sampling Visit to collect any AE and/or concomitant medication data

Phone Contact			
Did the participant receive phone contact from the site after the sampling visit?	• yes • no		ØP
	Date of contact:	09 / 01 / 2015 7	4
	Time of contact:	: hh:mm	Ø P
Were there any adverse events?	○ yes ○ no		ØP
Is this participant interested in attending a repeat sampling visit?	○ yes ○ no		4



AE Log

- AEs must be documented from the point of enrolment until procedures for the final study visit have been completed
- The AE log CRF should be completed within 48 hours of becoming aware of the event





SAEs

 SAEs must also be documented using the SAE CRF which will trigger an email to to Central Coordination, Chief Investigator, Medical Monitor and Site Principal Investigator/Coordinator


General			
Date of serious adverse event report:	01 / 14 / 2016 🗖 (format: "mm/dd/yyyy")		20
Serious Adverse Event			
Serious Adverse Events reported in the AE log No Adverse Events found where field 'SAE' set to yes			
AE number:			20
Start date of serious adverse event:	☐ (format: "mm/dd/yyyy")		20
Is the serious adverse event ongoing:	○ yes ○ no		Ø Ø
Was this an expected serious adverse event:	○ yes ○ no		E 0
Brief description of participant:	Sex:	female	20
	Age:	50	20
SAE Verbatim term:			Ø P
Brief description of the nature of the serious adverse event:			Ø Ø
Category (outcome) of the serious adverse event:	Death:	○ yes ○ no	Ø ø
	Disability/incapacity:	○ yes ○ no	
	Life-theatening:	○ yes ○ no	20
	Congenital anomaly/birth defect:	○ yes ○ no	@ @
	Hospitalization-initial or prolonged:	○ yes ○ no	20
	Required intervention to prevent permanent impairment:	○ yes ○ no	20
	None of the above:	○ yes ○ no	20
Outcome:	resolved; no sequelae ongoing; no treatment ongoing; undergoing treatment residual effects present; no treatment residual effects present; undergoing treatment death unknown		20
Describe any medical, behavioral, or other interventions taken as a result of this SAE:			40
Status of this report:	Final report:	0	20
Was the participant withdrawn from the research due to this SAE:	○ yes ○ no		20



Repeat Sampling Visit

4-8 weeks after initial LP

 Up to 20 participants per cohort will be invited to return for a Repeat Sampling Visit 4-8 weeks after their Sampling Visit





Data Monitoring

- Monitoring is conducted jointly by HDClarity CC and the Enroll-HD monitoring team
- Remote data review (RDR) of Enroll-HD forms will be conducted by the Enroll-HD monitors per the Enroll-HD monitoring plan (MP)
- RDR of HDClarity-specific forms will be done by HDClarity CC
- Onsite intermin monitoring visits will be carried out by Enroll-HD monitors per the Enroll-HD MP (i.e. frequency of visits will not change), with additional time allowed for review of HDClarity SMF



Payment

- A participant visit should be closed and remote monitored for the payment event(s) to be triggered
- The EDC will generate monthly accounting reports for each site, documenting number and type of visits that have been remotely monitored
- Payment event(s) are triggered via the Greenphire system as for Enroll-HD with additional exceptional payments as required for unscheduled visits (e.g. rescreening)



Other Documents

- Standard neurological examination & brief general examination check-list
- Standard Operating Procedures; Lumbar CSF Collection, Onsite CSF Processing, Onsite Serum & Plasma Processing, Sample Storage & Shipment, AE reporting and lab manual
- Two training videos; The first will demonstrate CSF samples collection at UCL, and a second will demonstrate CSF and blood processing at the site.
- EDC User Guide (specific to HDClarity)
- Premature End of Study form



Biosampling Kits Ordering kits and shipment of samples

- HDClarity kits will be requested via the EDC
- Samples will be stored at the site at -80 °C and must be shipped within 2 months of sampling
- Samples to be shipped include CSF, Cells from CSF, Serum, and Plasma.
- The Bulk Shipment Request form on the EDC is completed immediately after the shipment leaves the site.



Each participant kit contains four sub-kits

Lumbar Puncture sub-kit

- 4 x 50ml collection tubes
- 2 x atraumatic 22G spinal needles
- Sterile Wound pack
- 2 x 10ml syringes
- Tegaderm dressing
- Gauze
- 2 x 25G needles 2x 21G needles 2 x 18G needles





Blood Collection subkit

- 4 x Lithium Heparin tubes
- 1 x Serum tube
- 1 x Push-button Vacutainer blood collection set
- 2 x Vacutainers (spare)
- 2 x waterproof plasters
- 3 x Alcohol prep pads
- Tourniquet
- Sterile gauze





Blood Processing sub-kit

- 75 x cryovials labeled 'Plasma' + kit ID and barcode
- 3 x cryovials labeled Serum + kit
 ID and barcode
- 1x cryovial rack labeled Plasma
 + kit ID and 1D barcode
- 50 ml plasma tube
- 5 x polypropylene pipette tips
- 2 x polypropylene Pasteur pipettes with pipette teat





CSF Processing sub-kit

- 75 x cryovials labeled 'CSF' + kit
 ID and barcode
- 1 x cryovial labeled Cells 'CSF' + kit ID and barcode
- Cryovial rack labeled 'CSF' + kit
 ID and barcode
- 1.5ml RNAlater solution
- 30ml CSF supernatant tube labelled with kit ID and barcode
- 5 x polypropylene pipette tips
- 2 x polypropylene Pasteur pipettes with pipette teat



